Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
ROVI has commenced the marketing of its enoxaparin biosimilar in Spain
Wed, 19/09/2018 - 12:15
0 min
Español
IMG_0229.jpg
Download related document
Select rating
Give ROVI has commenced the marketing of its enoxaparin biosimilar in Spain 1/5
Give ROVI has commenced the marketing of its enoxaparin biosimilar in Spain 2/5
Give ROVI has commenced the marketing of its enoxaparin biosimilar in Spain 3/5
Give ROVI has commenced the marketing of its enoxaparin biosimilar in Spain 4/5
Give ROVI has commenced the marketing of its enoxaparin biosimilar in Spain 5/5
No votes yet
Related
ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French...
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has reached an agreement with a subsidiary of MSD (“MSD”) whereby ROVI acquires certain...
2 min
15/02/2019
ROVI acquires Falithrom® for the German market
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the purchase of Falithrom®, which was owned by Hexal AG (“Hexal”), a company...
1 min
09/01/2019
9M 2018 Results presentation
0 min
06/11/2018
See More
Email
Facebook
Twitter
LinkedIn
IMG_0229.jpg